- Home
- PRT vs CRVO Comparison
PRT vs CRVO Comparison
Compare PRT & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRT | CRVO |
|---|---|---|
| Founded | 2017 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.6M | 25.9M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | PRT | CRVO |
|---|---|---|
| Price | $2.20 | $2.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 25.6K | ★ 331.6K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | ★ 13.45% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,006,510.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.82 | $2.13 |
| 52 Week High | $4.12 | $10.89 |
Technical Indicators
Market Signals| Indicator | PRT | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 46.50 | 41.12 |
| Support Level | $2.02 | $2.43 |
| Resistance Level | $2.34 | $3.20 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 29.03 | 24.03 |
Price Performance
Historical ComparisonAbout PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.